There's a reproducibility crisis in life science. Here's how we're helping to beat it

A heartbreaking amount of time, resources, and hard work gets thrown away on irreproducible science. $28 billion gets wasted on unrepeatable preclinical research every year in the USA alone1 – that’s more than half the National Institutes of Health’s annual medical research budget.

A group of scientists working together in the lab

style

no-section-padding

70% of researchers can't reproduce another scientists' results. The stat is represented as a pie chart in the shape and style on the globe.

36% of experimental failures are caused by ineffective reagents

1 in 2 scientists say they've failed to reproduce their own results

Every year, $3.5 billion is wasted on poorly characterized antibodies. That's enough to fund Cancer Research UK's research for seven years. Photo of a burning $100 bill.

Overcoming this reproducibility crisis is at the heart of what we do at abcam

That’s why we’re continually improving the quality of our antibody range to ensure the highest possible performance and reliability, and keep researchers moving forward. Since 2010, we’ve withdrawn over 60,000 products that haven’t kept up with our rising standards.

We have 32k recombinant antibodies providing higher specificity, sensitivity and consistency so you can find exactly what you need

We have 4.5k+ knockout-validated antibodies - the gold standard for target specificity, and for confidence in your results

We carry out up to 10 application tests on our antibodies so you can be sure they work in the application you care about

So far, 75% of our recombinant rabbit monoclonal antibodies have undergone biophysical quality control

“What’s great is that abcam has many recombinant antibodies validated by knockout, which gives us a lot of confidence in the results.”

Dr Graham Heieis, Leiden Medical Center

“Our mission is to help scientists achieve their discoveries faster, and providing reagents that work the first time, every time, is key to fulfilling this goal.”

Dr Alejandra Solache, Abcam’s Senior Vice President of Research and Development

References

Freedman, L., Cockburn, I. & Simcoe, T. The Economics of Reproducibility in Preclinical Research. PLOS Biology 13, e1002165 (2015).
Baker, M. 1,500 scientists lift the lid on reproducibility. Nature 533, 452–454 (2016).

Learn more about our precision recombinant antibodies and the difference they can make to your research

Browse recombinant antibodies